文献速递胸部肿瘤放疗

超中心、中心和旁纵隔肺肿瘤立体定向体部放疗后的肿瘤控制与毒性

Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors.
PubMed 文献 · Pract Radiat Oncol · 2018-11-26

本研究回顾了2009年9月至2017年7月接受立体定向体部放疗(SBRT)的68例中央型肺肿瘤患者(共69个肿瘤,包括14个超中心、15个旁纵隔和39个中心肿瘤),比较其毒性、疾病控制和生存率。结果显示三组2年局部控制率和总生存率相似,但超中心肿瘤的2级及以上毒性风险增加。

要点

  • 超中心、中心和旁纵隔肺肿瘤SBRT后2年局部控制率和总生存率相似。
  • 超中心肿瘤2年2级及以上毒性发生率为57.6%,高于中心的14.2%和旁纵隔的7.1%。
  • 一例超中心肿瘤患者发生5级呼吸衰竭。

核心结论

  • 超中心、中心和旁纵隔肺肿瘤SBRT后的肿瘤学结局相似,主要采用5次分割方案时2年局部控制率超过85%。
  • 在本患者队列中,超中心肺肿瘤与毒性风险增加相关。
  • 需要额外研究以尽量减少超中心肿瘤的毒性。

研究设计与样本

  • 回顾性分析了2009年9月至2017年7月间接受SBRT的中央型肺肿瘤患者的记录。
  • 共识别68例患者、69个中央型肺肿瘤,包括14个超中心、15个旁纵隔和39个中心肿瘤。
  • 53例为早期肺癌,15例为肺转移。
  • 处方剂量为40 Gy至60 Gy,分3至8次。
  • 大多数患者采用5次分割(83%),其次为8次分割(10%)。

主要发现

  • 超中心、中心和旁纵隔肿瘤的2年局部控制率分别为89%、85%和93%(P = .72)。
  • 超中心、中心和旁纵隔肿瘤的2年总生存率分别为76%、73%和72%(P = .75)。
  • 超中心、中心和旁纵隔肿瘤的2年2级及以上毒性发生率分别为57.6%、14.2%和7.1%(P = .007)。
  • 一例超中心肿瘤患者发生5级呼吸衰竭。

关键数值与推荐

  • 中心肿瘤定义为距离近端支气管树(PBT)2 cm以内。
  • 超中心肿瘤定义为计划靶体积触及PBT或食管。
  • 旁纵隔肿瘤定义为触及纵隔胸膜。
  • 毒性采用不良事件通用术语标准4.03版评分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要额外研究以尽量减少超中心肿瘤的毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Increased rates of toxicity have been described after stereotactic body radiation therapy (SBRT) for central lung tumors within 2 cm of the proximal bronchial tree (PBT). Recent studies have defined a new class of ultracentral tumors. We report our experience treating ultracentral, central, and paramediastinal tumors with SBRT and compare toxicity, disease control, and survival rates. METHODS AND MATERIALS: We reviewed the records of patients with central lung tumors treated with SBRT between September 2009 and July 2017. Tumors were classified as central if within 2 cm of the PBT, ultracentral if the planning target volume touched the PBT or esophagus, and paramediastinal if touching mediastinal pleura. Actuarial rates of grades 2+ and 3+ toxicity, local control (LC), and overall survival were assessed using the Kaplan-Meier method and compared using a log-rank test. Toxicity was scored with the Common Terminology Criteria for Adverse Events, version 4.03. RESULTS: We identified 68 patients with 69 central lung tumors, including 14 ultracentral, 15 paramediastinal, and 39 central tumors. Fifty-three patients were treated for early stage lung cancer and 15 for lung metastases. The prescribed dose ranged from 40 Gy to 60 Gy over 3 to 8 fractions. Most patients were treated using 5 fractions (83%), followed by 8 fractions (10%). Median follow-up was 19.7 months (range, 3.3-78.3 months). The 2-year estimates of LC (89%, 85%, and 93%, respectively; P = .72) and overall survival (76%, 73%, and 72%, respectively; P = .75) for ultracentral, central, and paramediastinal tumors were similar. Ultracentral tumors had an increased risk of grade 2+ toxicity (57.6% vs 14.2% vs 7.1%; P = .007) at 2 years. One patient with an ultracentral tumor developed grade 5 respiratory failure. CONCLUSIONS: The oncologic outcomes after SBRT for ultracentral, central, and paramediastinal lung tumors were similar, with LC exceeding 85% at 2 years using predominantly 5-fraction schedules. Ultracentral lung tumors were associated with an increased risk of toxicity in our patient cohort. Additional studies are needed to minimize toxicity for ultracentral tumors.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Nguyen KNB, Hause DJ, Novak J, et al. Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors. Pract Radiat Oncol. 2018. PMID: 30496842. doi:10.1016/j.prro.2018.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。